Copper Cu 64 Dotatate Levels and Effects while Breastfeeding
Summary of Use during Lactation
Copper Cu 64 dotatate is a radiolabeled somatostatin analog indicated for use with positron emission tomography for localization of somatostatin receptor positive neuroendocrine tumors. No information is available on the use of copper Cu 64 dotatate during breastfeeding. The manufacturer recommends that breastfeeding be interrupted for 12 hours after copper Cu 64 dotatate administration.
Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level, she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[1]
Drug Levels
Copper Cu 64 decays to nickel 64 (Ni 64) with a half-life of 12.7 hours by positron emission followed by emission of two 511 keV annihilation photons. It also decays to Ni 64 by electron capture and to zinc 64 by beta decay.
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Copper Cu 64 Dotatate
CAS Registry Number
1426155-87-4
Drug Class
Breast Feeding
Lactation
Radiopharmaceuticals
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.